Iterum Therapeutics Net Worth
Iterum Therapeutics Net Worth Breakdown | ITRM |
Iterum Therapeutics Net Worth Analysis
Iterum Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Iterum Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Iterum Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Iterum Therapeutics' net worth analysis. One common approach is to calculate Iterum Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Iterum Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Iterum Therapeutics' net worth. This approach calculates the present value of Iterum Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Iterum Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Iterum Therapeutics' net worth. This involves comparing Iterum Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Iterum Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Iterum Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iterum Therapeutics' net worth research are outlined below:
| Iterum Therapeutics is way too risky over 90 days horizon | |
| Iterum Therapeutics appears to be risky and price may revert if volatility continues | |
| Iterum Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (38.37 M) with profit before overhead, payroll, taxes, and interest of 37 K. | |
| Iterum Therapeutics PLC currently holds about 68.91 M in cash with (39.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iterum Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Iterum Therapeutics Regains Full Nasdaq Compliance |
Iterum Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iterum Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iterum Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Iterum Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iterum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iterum Therapeutics PLC backward and forwards among themselves. Iterum Therapeutics' institutional investor refers to the entity that pools money to purchase Iterum Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-06-30 | 12.0 | Hm Payson & Co | 2024-09-30 | 3.0 | Ubs Group Ag | 2024-09-30 | 1.0 | Jpmorgan Chase & Co | 2024-09-30 | 1.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 | Tower Research Capital Llc | 2024-09-30 | 0.0 | Ancora Advisors Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Kelly Financial Services Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 1.3 M | New Leaf Venture Partners, L.l.c. | 2024-09-30 | 345 K |
Follow Iterum Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.64 M.Market Cap |
|
Project Iterum Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.46) | (1.53) | |
| Return On Capital Employed | (3.73) | (3.54) | |
| Return On Assets | (1.46) | (1.53) | |
| Return On Equity | 5.99 | 6.29 |
When accessing Iterum Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Iterum Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iterum Therapeutics' profitability and make more informed investment decisions.
Evaluate Iterum Therapeutics' management efficiency
Iterum Therapeutics PLC has return on total asset (ROA) of (0.7335) % which means that it has lost $0.7335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5568) %, meaning that it created substantial loss on money invested by shareholders. Iterum Therapeutics' management efficiency ratios could be used to measure how well Iterum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of December 2024, Return On Equity is likely to grow to 6.29, while Return On Tangible Assets are likely to drop (1.53). At this time, Iterum Therapeutics' Other Current Assets are very stable compared to the past year. As of the 4th of December 2024, Total Current Assets is likely to grow to about 47 M, while Net Tangible Assets are likely to drop about 14.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.49) | (0.47) | |
| Tangible Book Value Per Share | (0.49) | (0.47) | |
| Enterprise Value Over EBITDA | (1.11) | (1.17) | |
| Price Book Value Ratio | (3.99) | (4.19) | |
| Enterprise Value Multiple | (1.11) | (1.17) | |
| Price Fair Value | (3.99) | (4.19) | |
| Enterprise Value | 38.4 M | 36.5 M |
The strategic initiatives led by Iterum Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 105.2207 | Quarterly Revenue Growth (1.00) | Return On Equity (5.56) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iterum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iterum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iterum Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iterum Therapeutics Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of October 2024 Other Reports | ViewVerify | |
| 30th of September 2024 Other Reports | ViewVerify | |
F4 | 12th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Iterum Therapeutics Earnings per Share Projection vs Actual
Iterum Therapeutics Corporate Management
| Sailaja MD | Chief Officer | Profile | |
| Tom Loughman | Senior Operations | Profile | |
| Steven MD | Senior Development | Profile | |
| Louise Barrett | Senior Secretary | Profile | |
| Michael MD | Strategic Director | Profile | |
| Judith Matthews | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.